Fast-growing CRO Enhances Ability to Offer Unified eClinical Platform to Sponsors CLEVELAND, Nov. 18
CLEVELAND, Nov. 18 /PRNewswire-FirstCall/ -- DATATRAK International, Inc.
(Nasdaq: DATA), a technology and services company focused on global eClinical
solutions for the clinical trials industry, today reported that it has signed
Diverse Lynx to its CRO Connect program.
DATATRAK's CRO Connect program is a non-exclusive enterprise agreement and
accreditation relationship that empowers CROs to design and deploy their own
EDC trials using DATATRAK's unified eClinical platform. As a CRO Connect
partner, Diverse Lynx will be able to offer eClinical services to its clients
through a standardize offering.
"We are pleased to add Diverse Lynx to our CRO Connect program," stated
Dr. Jeffrey A. Green, Chief Executive Officer of DATATRAK International, Inc.
"Collaboratively, this program allows Diverse Lynx to offer our standardized
eClinical platform to best serve their sponsor's clinical trial needs. Our
CRO model allows them to offer very predictable research and development costs
while eliminating wasted time involved with negotiation and contracting under
the trial-by-trial mode. This model has tremendous advantages to DATATRAK and
Diverse Lynx with solid visibility of revenues over a multi-year period of
time combined with a greatly diminished cost of sales."
"Our partnership with DATATRAK International is a big step towards
offering absolute clinical data management services for data capture,
processing, analysis and management services in the most cost effective
approach with the highest quality. We now have a strong data management
infrastructure to match our organization in Europe, Japan and Asian countries,
covering over 20 countries," said Shubhendra Varma, President of Diverse Lynx.
"At Diverse Lynx, we take this partnership several steps further by
emphasizing long-term, value-added relationships and a commitment to
understand our sponsors' business needs."
About DATATRAK International:
DATATRAK International, Inc. is a worldwide technology company focused on
the provision of multi-component eClinical solutions and related services for
the clinical trials industry. The Company delivers a complete portfolio of
software products that were created in order to accelerate clinical research
data from investigative sites to clinical trial sponsors and ultimately the
FDA, faster and more efficiently than manual methods or loosely integrated
technologies. DATATRAK's eClinical software suite can be deployed worldwide
through an ASP offering or in a licensed Enterprise Transfer model that fully
empowers its clients. The DATATRAK software suite and its earlier versions
have successfully supported hundreds of international clinical trials
involving thousands of clinical research sites and encompassing tens of
thousands of patients in 59 countries. DATATRAK International, Inc.'s product
suite has been utilized in some aspect of the clinical development of 16 drugs
and one device that have received regulatory approval from either the United
States Food and Drug Administration or counterpart European bodies. DATATRAK
International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas.
Its common stock is listed on the NASDAQ stock Market under the ticker symbol
"DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net .
About Diverse Lynx:
Diverse Lynx is a rapidly growing Information Technology and, Clinical
Research and Data Management Company focused on providing contract research
services to develop drugs and clinical trials to leading pharmaceutical,
Biotech companies and government agencies globally. Its IT division provides a
litany of diverse services that include staff supplementation through
workforce contracting, e-business consulting, web-based applications, Client
Server Applications, network solutions and other in-house and offshore
software developments. Its Clinical Trial & Data Management division offers
clinical research support to the global pharmaceutical industry and supports
sponsors in their clinical trial management, pharmacovigilance and safety risk
management, data management and regulatory affairs in the area of Oncology,
Neurology, Psychiatry, Cardiology, Nephrology, Infectious Diseases and
therapeutics vaccines. Headquartered out of New Jersey, USA with an office in
India, Diverse Lynx has collaboration throughout Europe as well as in Japan
and Russia. For more information please visit Diverse Lynx website at
www.diverselynx.com .
Except for the historical information contained in this press release, the
statements made in this release are forward-looking statements. These
forward-looking statements are made based on management's expectations and
beliefs concerning future events impacting the Company and are subject to
uncertainties and factors (including those specified below) which are
difficult to predict and, in many instances, are beyond the control of the
Company. Factors that may cause actual results to differ materially from those
in the forward-looking statements include the limited operating history on
which the Company's performance can be evaluated; the ability of the Company
to continue to enhance its software products to meet customer and market
needs; fluctuations in the Company's quarterly results; the viability of the
Company's business strategy and its early stage of development; the timing of
clinical trial sponsor decisions to conduct new clinical trials or cancel or
delay ongoing trials; the Company's dependence on major customers; government
regulation associated with clinical trials and the approval of new drugs; the
ability of the Company to compete in the emerging EDC market; losses that
potentially could be incurred from breaches of contracts or loss of customer
data; the inability to protect intellectual property rights or the
infringement upon other's intellectual property rights; the Company's success
in integrating its acquisition's operations into its own operations and the
costs associated with maintaining and/or developing two product suites; and
general economic conditions such as the rate of employment, inflation,
interest rates and the condition of capital markets. This list of factors is
not all inclusive. In addition, the Company's success depends on the outcome
of various strategic initiatives it has undertaken, all of which are based on
assumptions made by the Company concerning trends in the clinical research
market and the health care industry. The Company undertakes no obligation to
update publicly or revise any forward-looking statement.
SOURCE DATATRAK International, Inc.
